Feasibility and efficacy of sequentially performed endovascular stenting and Iodine-125 brachytherapy for malignant superior vena cava syndrome (SVCS) were evaluated. Thirtyfour patients with malignant SVCS caused by NSCLC underwent sequential treatment of endovascular stenting and Iodine-125 brachytherapy. SVCS was diagnosed in all patients by CT images or vena-cavography. Pathology diagnosis was acquired by image guided biopsy. Endovascular stent placement was performed as first-line treatment for symptom relief. CTguided Iodine-125 seed implantation performed 24hr after stenting. Clinical end points were resolution of symptoms and local efficacy of primary malignancy regression. Symptom relief rate was >90% after 24hr and 97% after 3 months. No migration of seeds or restenosis occurred in any patient. The local efficacy (defined as either partial or complete response)
Introduction
Superior vena cava syndrome has a malignant cause in more than 90% of patients, which results in impairment of lifestyle, and sometimes causes a life-threatening medical emergency in many patients (1, 2) . Common clinical findings of SVCS are headache, dyspnea, cough, and cervio-facial or upper limb edema. Nonsmall cell lung cancer can cause SVCS, and has a lower response rate to chemoradiotherapy compared to small cell lung cancer or lymphoma. Endovascular stenting provides an urgent symptomatic relief for malignant SVCS. Although the prognosis of malignant SVCS is linked to the tumor stage (3-7), local control may provide symptomatic relief and reduce recurrence and distant metastasis.
In this study, sequential treatment of stenting and CT-guided Iodine-125 brachytherapy was performed for patients with malignant SVCS, in order to relieve symptomatology.
Abbreviations: SVCS, Superior vena cava syndrome; NSCLC, Non-small cell carcinoma lung cancer; TPS, Treatment plan system. 
Materials and Methods

Patients
From Jan 2005 to Apr 2008, 34 patients (19 men and 15 women) with malignant SVCS caused by NSCLC underwent sequential treatment of endovascular stenting and CTguided Iodine-125 brachytherapy. No patient had previous treatment. The mean age was 67 years (range, 54-79 years). All patients presented with the clinical diagnosis of SVCS confirmed by enhanced CT images and phlebo graphy (Figures 1 and 2). The histologic diagnosis was obtained by CT or ultrasonographically guided percutaneous biopsy in all patients. The main symptoms were facial, cervical or/and upper limb edema (34 cases), headache (9 cases), collateral branches in superior chest wall (19 cases), pleural effusion (4 cases) and dyspnea (25 cases). This study was approved by our institutional review board and all patients participating in this clinical trial signed written informed-consent documents before treatment.
All tumors studied were limited to locally advanced stage IIIB. The mean tumor size was 6.8 cm (range 5.2-13.7cm) measured by contrast CT images. The obstruction degree of the caval lumen was > 75% in all patients. Using the classification of Stanford et al., (9) , SVCS in our patients was classified as type I, type II, type III and type IV in 7, 12, 9 and 6 patients, respectively. SVC Caliber measurement was based on digital subtraction phlebography images.
All patients had coagulation parameters and complete blood counts as well as coagulation studies performed before treatment. All patients had vital signs (pulse, blood pressure, electrocardiography, saturation of blood oxygen) monitored and nasal oxygen inhalation during treatment (both stenting and Iodine-125 brachytherapy).
Methods
Endovascular Stent Placement:
Patients underwent stenting as the first-line treatment in order to relieve the obstructive symptoms. This procedure was performed with local anesthesia (2% lidocaine) without sedatives. Stent placement was carried out in the angiography room under the monitoring of a digital subtraction apparatus. Access via the right femoral vein was used both for the phlebography as well as for stent placement in all patients. Since the stent placement technique is well described (4-8), we discuss briefly the process of stent insertion.
A 10 F vascular sheath was first introduced into femoral vein with Sedinger's skill. Through which a hydrophilic guide wire (Terumo, Japan) and a 5 F multipurpose catheter were coaxially introduced to allow access to the SVC. A self-expanding Z-stent was placed across the stenosis by means of a high supporting guide wire under high-resolution fluoroscopy. Balloon dilatation was performed before stent placement. The diameter of the stent is selected to be 
CT-guided Iodine-125 Brachytherapy:
Percutaneous CT-guided Iodine-125 brachytherapy was performed 24 hours after successful endovascular stent placement under local anesthesia. Due to the multiple needle tracts needed for Iodine-125 source distribution uniformity, 10 mg of Diazepam was given intramuscularly injection prior to the procedure.
A MX8000 four-spiral CT scanner with Pinpoint optical navigating system (Philips Medical Systems, Cleveland Ohio) was used for lesion location and puncture guidance. An 18-gauge disposable spinal needle (Dr.Japan Co, Tokyo, Japan) was used for implantation of Iodine-125 seed (Synco Pharmaceutical Co., Shanghai, China). Pre-procedure computerized treatment planning was performed on a Treatment Plan System (TPS, Hokai Co., Shanghai, China). The mean radioactivity of the Iodine-125 seeds was 0.7mci (0.6-0.9mci). According to enhancement CT images to delineate the target, the gross tumor volume was enlarged 5-10mm circumferentialy to form the planning target volume. The prescription dose (matched peripheral dose) was 140Gy to the planning target volume. All CT-guided needle punctures were performed in the supine position. The skin of needle entry site was prepared in a sterile fashion. Two-percent lidocaine was injected for local anaesthesia. An 18-gauge needle was advanced in a stepwise fashion with CT scan guidance. Radioactive sources were implanted as linear type according to pre-implant planning. The Iodine-125 seeds were implanted one by one with the gradual needle withdrawl ( Figures 5 and 6 ). The interval between seeds was 5-7mm. After implantation, the post procedure CT images were verified (Figure 7) . Patients who are unable to tolerate the entire implant in one session underwent a second procedure. Forty-two implants (mean, 1.2 times) were performed in 34 patients, with twenty-seven patients in a single implant, six patients had two implants and one patient had three implants. Each procedure required a mean of 84 min (range, 60-150 min). No major acute complications occurred. A mean of 56.5 Iodine-125 seeds (range, 37-113 seeds) were used for each implant. All seeds were accounted for at each follow up scan. Patients without bleeding complications were given oral anticoagulant therapy after implantation.
Clinical Follow-up and Statistics
Patients were assessed for dyspnea, edema, venous engorgement and headache. Response was assessed 24hr after the endovascular stenting procedure, and at 1, 2 and 3 months later. A contrast enhanced CT scan of chest for each patient was performed at 1, 3 and 6 months after treatment and every 3 months thereafter. According to response evaluation criteria in solid tumors (RECIST) (10), Local tumor response was defined as complete response, partial response (PR, 30% decreased), progression of disease (PD, 20% increased) and stable disease (Neither PR or PD criteria met). Acute as well as late complications were evaluated. Iodine-125 seed loss or migration was also monitored by CT images (Figure 8 ). Statistics were performed with the SPSS Base 14.0 Statistical Software Package (SPSS, Chicago, IL). Results were analyzed by Kaplan-Meier survival curve.
Results
Stenting procedures were technically successful in all patients. A single stent was performed in each patient. There were no technical complications and no stent migration was observed. No stent restenosis occurred during follow-up.
Complete symptomatic response defined as resolution of the acute SVCS occurred in > 90% patients 24hr after stenting. Resolution of dyspnea occurred in 71% patients. However, at the 6 months follow up, the rate of resolution of all symptomatology exceeded 90% (Table I) .
Local tumor response is shown in Table II . Mean SVCS free survival time was 305 days (range 120-960 days) ( Figure 9 ). Mean overall survival time was 320 days (range 120-960 days) for malignant disease after combined treatment ( Figure 10 ). Two patients were still alive at 301 days. The same patients were symptom free at 338 days, and are alive at the time of publication. Mean distant metastasis free survival time was 232 days (Figure 11 ). One patient died from sudden cardiac death (182 days). Twenty-five patients (73.5%) died of disease, but were free of local symptomatology at the time of their deaths. Six patients (17.6%) had dyspnea relieved after reintervention of Iodine-125 seed implantation. No obstruction or restenosis occurred during follow-up in any patient. There was no acute or long-term toxicity related to radiation (radiation pneumonia, radiation esophagitis and radiation myelitis) following implantation.
Discussion
SVCS is a result of impaired venous drainage when the superior vena cava is compressed extra-or intraluminally, causing venous hypertension and congestion of the veins draining into the superior vena cava (11) (12) (13) (14) . The primary causes of SVCS are intrathoracic malignancies. About 10% of patients with a right-sided malignant intrathoracic mass lesion developed SVCS and more than 70% SVCS are caused by lung cancer (12-20) .
The treatment of malignant SVCS includes chemotherapy, radiotherapy, by-pass surgery and endovascular stenting. Because the patients with SVCS are usually having terminal disease, palliative therapy is the usual goal. Charnsangavej et al., (21) reported on stent implantation for SVCS in experimental animals; and subsequently in human in the 1990's (22) (23) (24) (25) . With the development of interventional radiography and manufacturing technology, stent placement has become well established. The urgent relief of symptoms by stents makes endovascular stenting the first choice of treatment for SVCS rather than emergency radiation therapy in some patients.
In our group, endovascular stenting was performed for symptom relief. Combination treatment of subsequent CT-guided Iodine-125 seed implantation was performed for local treatment of disease. We agree with Lanciego et al., (26) that stenting should be the first-line treatment for malignant SVCS, because the rapid relief of symptoms calms patient fears more quickly. The Z-stent was chosen cause of our familiarity with the device. There is no significant deference between various types of stents with respect to symptom response or with the frequency of associated complications (27) (28) (29) . The high successful rate of stent placement and high response of symptom relief also proved the safety and efficacy of stenting for SVCS treatment. Despite the fact that endovascular stent placement provides a minimally invasive and effective treatment for malignant SVCS, there are other symptoms caused by mediastinal masses such as dyspnea and hoarseness, which cannot thoroughly be relieved by stenting. Although traditional chemotherapy and radiotherapy or combined treatment after endovascular stenting shows efficacy in primary disease treatment, the side effects of these treatments can cause nausea, vomiting, anorexia, skin irritation and esophagitis, decreasing quality of life. In our study, Iodine-125 brachytherapy alleviated the tumor burden, and prevented the restenosis caused by disease progression.
Iodine-125 brachytherapy has been used to treat prostate cancer for decades, and has been used for treating other type of tumors in liver, brain and lung (30-33). The efficacy and safety was demonstrated by both animal experiment and clinical studies (33-36). Iodine-125 sources can be placed safely and accurately under CT guidance, ensuring that the therapeutic dose delivery is confined to the shape of target lesion. The low-energy radioactive sources have limited tissue penetration, which allows for a sharp drop-off of radiation dose at the edge of the target lesion, limiting radiation delivery to normal tissues and minimizing potential treatment-related complications. Likewise, radiation exposure to physicians, nursing personnel, and family members is negligible. Target lesion movement caused by respiration can significantly affect the accuracy of external beam therapy and compromise both lesion and normal-tissue dose and is generally not a factor for implantation of Iodine-125 seeds. Brachytherapy is also a one time treatment, compared with a protracted external radiotherapy, and is regarded as the ultimate conformal therapy.
CT-guided Iodine-125 seeds implant is a safe and repeatable treatment with low complications and side effects, and is well tolerated by patients. For NSCLC, it has been shown by multiple investigators that doses of greater than 80 Gy are needed to achieve maximum local control. Brachytherapy can deliver significantly higher doses and may be superior (30-32, 34, 36) .
Iodine-125 can be safely used in the treatment of SVCS patients with NSCLC following SVC stenting. Further investigation is warranted.
